logo.png
Orphazyme’s arimoclomol receives US Fast Track Designation in Amyotrophic Lateral Sclerosis
May 22, 2020 01:52 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement                                                                                       No....
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences Appoints Dr. Ken Rhodes as Senior Vice President, Therapeutics Discovery
May 18, 2020 07:30 ET | Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 18, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update
May 11, 2020 07:30 ET | Wave Life Sciences USA, Inc.
Data from both PRECISION-HD clinical trials expected in 2H 2020 Advancing clinical neurology pipeline − SNP3 and C9orf72 programs on track to initiate clinical development in 2H 2020 First...
download.jpg
BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS
February 11, 2020 06:00 ET | BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc., (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
download.jpg
BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference
February 04, 2020 04:45 ET | BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 04, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases,...
download.jpg
BrainStorm Issues 2019 Letter to Shareholders
December 18, 2019 05:00 ET | BrainStorm Cell Therapeutics Inc.
NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapeutics for neurodegenerative diseases, today issued a Letter to...
download.jpg
BrainStorm Selected as Buzz of BIO 2020 Winner
December 11, 2019 05:00 ET | BrainStorm Cell Therapeutics Inc.
NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND
December 09, 2019 03:15 ET | Orion Oyj
Orion Corporation                        Press release                               9 December at 10.15 EET Orion has studied the effects of oral levosimendan on respiratory function in patients...
Suun kautta annosteltavan levosimendaanin tutkimustuloksia esiteltiin kansainvälisessä ALS/MND symposiumissa
December 09, 2019 03:15 ET | Orion Oyj
ORION OYJ        LEHDISTÖTIEDOTE                                                  9.12.2019 klo 10.15 Orion on tutkinut suun kautta annosteltavan levosimendaanin vaikutusta ALS-potilaiden...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005) 
December 04, 2019 08:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...